Stock Research for CYTR

CYTR

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

CYTR Stock Chart & Research Data

The CYTR chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CYTR chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


CYTR Due diligence Resources & Stock Charts

The CYTR stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View CYTR Detailed Price Forecast - CNN Money CNN View CYTR Detailed Summary - Google Finance
Yahoo View CYTR Detailed Summary - Yahoo! Finance Zacks View CYTR Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View CYTR Trends & Analysis - Trade-Ideas Barrons View CYTR Major Holders - Barrons
NASDAQ View CYTR Call Transcripts - NASDAQ Seeking View CYTR Breaking News & Analysis - Seeking Alpha
Spotlight View CYTR Annual Report - CompanySpotlight.com OTC Report View CYTR OTC Short Report - OTCShortReport.com
TradeKing View CYTR Fundamentals - TradeKing Charts View CYTR SEC Filings - Bar Chart
WSJ View Historical Prices for CYTR - The WSJ Morningstar View Performance/Total Return for CYTR - Morningstar
MarketWatch View the Analyst Estimates for CYTR - MarketWatch CNBC View the Earnings History for CYTR - CNBC
StockMarketWatch View the CYTR Earnings - StockMarketWatch MacroAxis View CYTR Buy or Sell Recommendations - MacroAxis
Bullish View the CYTR Bullish Patterns - American Bulls Short Pains View CYTR Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View CYTR Stock Mentions - StockTwits PennyStocks View CYTR Stock Mentions - PennyStockTweets
Twitter View CYTR Stock Mentions - Twitter Invest Hub View CYTR Investment Forum News - Investor Hub
Yahoo View CYTR Stock Mentions - Yahoo! Message Board Seeking Alpha View CYTR Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for CYTR - SECform4.com Insider Cow View Insider Transactions for CYTR - Insider Cow
CNBC View CYTR Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for CYTR - OTC Markets
Yahoo View Insider Transactions for CYTR - Yahoo! Finance NASDAQ View Institutional Holdings for CYTR - NASDAQ


Stock Charts

FinViz View CYTR Stock Insight & Charts - FinViz.com StockCharts View CYTR Investment Charts - StockCharts.com
BarChart View CYTR Stock Overview & Charts - BarChart Trading View View CYTR User Generated Charts - Trading View


Latest Financial News for CYTR

CytRx Corporation Highlights NantCell Inc's Aldoxorubicin Clinical Data Presented at the American Society of Clinical Oncology 2018 Annual Meeting
Posted on Thursday June 07, 2018

LOS ANGELES, June 7, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted clinical data from partner NantCell's poster presentation on June 2, 2018 at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting, in Chicago. The data clearly demonstrates the lack of cardiac toxicity associated with treatment with aldoxorubicin.


CytRx Corporation Launches Centurion BioPharma Corporation to Advance LADR™ Albumin Binding Ultra-High Potency Oncology Drug Candidates
Posted on Monday June 04, 2018

LOS ANGELES, June 4, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the formation and launch of Centurion BioPharma Corporation, a private wholly owned subsidiary that will focus on advancing the Company's proprietary, albumin binding ultra-high potency LADR™ (Linker-Activated Drug Release) oncology drug candidates.  CytRx has transferred to Centurion BioPharma all of the assets, liabilities and personnel associated with its laboratory operations in Freiburg, Germany. Administrative Offices are located in Los Angeles, California.


CytRx Corporation to Present at 8th Annual LD Micro Invitational Conference
Posted on Wednesday May 30, 2018

LOS ANGELES, May 30, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Mr. John Caloz, Chief Financial Officer, will present at the 8th Annual LD Micro Invitational Conference on Tuesday, June 5, 2018 at 1:30 P.M. Pacific Daylight Time at the Luxe Sunset Boulevard Hotel in Bel-Air. Mr. Caloz will discuss the LADR™ platform, its broad potential in treating various tumor types, its advantages over antibody drug conjugates and an example of a LADR™ surrogate product proof of concept (aldoxorubicin).  He will also address the goal of obtaining pharmaceutical partnerships to develop the LADR™ pipeline candidates that are eligible for Investigational New Drug (IND)-enabling studies. In excess of 1,000 people are expected to attend the Invitational, to hear presentations from more than 200 leading microcap companies.


CytRx Corporation Highlights NantCell Inc's Aldoxorubicin Clinical Data to be Presented at the American Society of Clinical Oncology 2018 Annual Meeting
Posted on Thursday May 17, 2018

LOS ANGELES, May 17, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that clinical data showing the lack of cardiac toxicity associated with treatment with partner NantCell's aldoxorubicin will be featured in a poster presentation at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting, taking place June 1-5, 2018 in Chicago. The data were obtained from two clinical trials of aldoxorubicin, a rationally-engineered cytotoxic which employs a linker bound to albumin to deliver doxorubicin directly into the tumor.


Enter a stock symbol to view the stock details.